23 analysts have shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 15 | 4 | 0 | 0 |
| Last 30D | 0 | 1 | 1 | 0 | 0 |
| 1M Ago | 2 | 6 | 1 | 0 | 0 |
| 2M Ago | 0 | 3 | 2 | 0 | 0 |
| 3M Ago | 2 | 5 | 0 | 0 | 0 |
Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $1185.96, accompanied by a high estimate of $1300.00 and a low estimate of $1015.00. Highlighting a 0.1% decrease, the current average has fallen from the previous average price target of $1187.13.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Regeneron Pharmaceuticals among financial...
Login or create a forever free account to read this news
Sign up/Log in
